SELECTIVE LABELING AND LOCALIZATION OF THE M4 (M4) MUSCARINIC RECEPTOR SUBTYPE

被引:0
|
作者
FERRARIDILEO, G
WAELBROECK, M
MASH, DC
FLYNN, DD
机构
[1] UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL R189,MIAMI,FL 33101
[2] UNIV MIAMI,SCH MED,DEPT NEUROL,MIAMI,FL 33101
[3] FREE UNIV BRUSSELS,SCH MED,DEPT BIOCHEM & NUTR,B-1000 BRUSSELS,BELGIUM
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here a novel strategy for the selective labeling and localization of the M4 (m4) muscarinic receptor subtype, based on the distinct kinetics of the muscarinic antagonists dexetimide and N-methylscopolamine (NMS) and on the selectivity profile of guanylpirenzepine and AF-DX 116 for the m1-m5 muscarinic receptor subtypes expressed in CHO-K1 cells. Incubation with 10 nM dexetimide, a nonselective antagonist, resulted in >90% occupancy of each of the m1-m5 receptor subtypes. The relatively rapid rates of dexetimide dissociation from the mi, m2, and m4 receptor subtypes (t(1/2) values of <12.5 min) and the slower rates of dexetimide dissociation from the m3 and m5 receptor subtypes (tn values of 65 and 75 min, respectively) favored the labeling of the mi, m2, and m4 receptor subtypes with short incubations with [H-3]NMS. Inclusion of 200 nM guanylpirenzepine and 250 nM AF-DX 116 prevented the binding of [H-3]NMS to the majority of the mi and m2 receptor subtypes, respectively, resulting in primary labeling of the m4 receptor subtype. Brief dissociation of the radioligand in the presence of 1 mu M atropine improved the ratio of m4 to m2 labeling by selectively removing [H-3]NMS from the m2 subtype. Under these conditions, the ratio of [H-3]NMS binding to the m4 versus mi, m2, m3, and m5 receptor subtypes was 4:1. In vitro autoradiography combined with these m4-selective labeling conditions demonstrated that the M4 (m4) receptor subtype was localized to the primary visual area (V1, area 17, occipital cortex) and the basal ganglia, a distribution distinct from that demonstrated for the M1 (mi), M2 (m2), and M3 (m3) receptor subtypes. These results demonstrate that a combination of the distinct kinetics of dexetimide and NMS and the receptor subtype selectivity of guanylpirenzepine and AF-DX 116 provides a valuable labeling strategy to examine the distribution and localization of the M4 (m4) muscarinic receptor subtype in brain, peripheral tissues, and cell lines.
引用
收藏
页码:1028 / 1035
页数:8
相关论文
共 50 条
  • [21] Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice
    Tzavaral, ET
    Bymaster, FP
    Felder, CC
    Wade, M
    Gomeza, J
    Wess, J
    McKinzie, DL
    Nomikos, GG
    [J]. MOLECULAR PSYCHIATRY, 2003, 8 (07) : 673 - 679
  • [22] Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice
    E T Tzavara
    F P Bymaster
    C C Felder
    M Wade
    J Gomeza
    J Wess
    D L McKinzie
    G G Nomikos
    [J]. Molecular Psychiatry, 2003, 8 : 673 - 679
  • [23] Involvement of a Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4 Preferring Muscarinic Receptor Agonist Xanomeline
    Dencker, Ditte
    Wortwein, Gitta
    Weikop, Pia
    Jeon, Jongrye
    Thomsen, Morgane
    Sager, Thomas N.
    Mork, Arne
    Woldbye, David P. D.
    Wess, Juergen
    Fink-Jensen, Anders
    [J]. JOURNAL OF NEUROSCIENCE, 2011, 31 (16): : 5905 - 5908
  • [24] Muscarinic toxin selective for m4 receptors impairs memory in the rat
    Jerusalinsky, D
    Kornisiuk, E
    Alfaro, P
    Quillfeldt, J
    Alonso, M
    Verde, ER
    Cerveñansky, C
    Harvey, A
    [J]. NEUROREPORT, 1998, 9 (07) : 1407 - 1411
  • [25] Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
    Chan, W. Y.
    McKinzie, D. L.
    Bose, S.
    Mitchell, S. N.
    Witkin, J. M.
    Thompson, R. C.
    Christopoulos, A.
    Lazareno, S.
    Birdsall, N. J. M.
    Bymaster, F. P.
    Felder, C. C.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (31) : 10978 - 10983
  • [26] The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders
    Chambers, Nicole E.
    Millett, Michael
    Moehle, Mark S.
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2023, 51 (02) : 691 - 702
  • [27] BINDING OF SELECTIVE ANTAGONISTS TO 4 MUSCARINIC RECEPTORS (M1 TO M4) IN RAT FOREBRAIN
    WAELBROECK, M
    TASTENOY, M
    CAMUS, J
    CHRISTOPHE, J
    [J]. MOLECULAR PHARMACOLOGY, 1990, 38 (02) : 267 - 273
  • [28] Muscarinic M4 receptor changes in the hippocampus and entorhinal cortex of adrenalectomized
    Mulugeta, E
    Fahim, MA
    Hasan, MY
    El-Bakri, N
    Winblad, B
    Karlsson, E
    Adem, A
    [J]. FASEB JOURNAL, 2004, 18 (05): : A1256 - A1256
  • [29] Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
    Pozhidaev, Ivan, V
    Boiko, Anastasiia S.
    Loonen, Anton J. M.
    Paderina, Diana Z.
    Fedorenko, Olga Yu
    Tenin, Gennadiy
    Kornetova, Elena G.
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Wilffert, Bob
    Ivanova, Svetlana A.
    [J]. APPLICATION OF CLINICAL GENETICS, 2020, 13 : 97 - 105
  • [30] Altered distribution of M2 and M4 muscarinic receptor expression in vitiligo
    Chaichalotornkul, Sirintip
    Udompataikul, Montree
    Showpittapornchai, Udomsri
    Palungwachira, Piti
    Pradidarcheep, Wisuit
    [J]. JOURNAL OF DERMATOLOGY, 2011, 38 (05): : 493 - 497